Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

ZTS Q1 2026

Zoetis's first-quarter 2026 update reflected continued companion-animal demand, growth-product contributions in pain, parasiticides and dermatology and resilient livestock operations across geographies.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand.
  • Librela and Solensia can expand treatment of chronic pain in dogs and cats as veterinarian familiarity grows.
  • New vaccines, diagnostics and monoclonal antibodies can extend a differentiated portfolio.

Risks that still need monitoring

  • Product safety

    Adverse-event concerns or label changes could slow adoption of important companion-animal products.

  • Veterinary capacity

    Clinic staffing constraints and affordability pressure can limit visits, diagnoses and treatment starts.

  • Livestock volatility

    Disease outbreaks, commodity economics and regulation can cause abrupt changes in producer demand.

Primary sources

Zoetis Reports First Quarter 2026 ResultsZoetis Inc. · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 5/5/2026, 12:00:00 AM

Open original source
Zoetis Inc. Investor RelationsZoetis Inc. · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Zoetis SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 5/5/2026, 12:00:00 AM

Open original source

Continue research

Open risk researchReturn to full stock research